Business
MedMira Extends Market Reach into Southeast Asia with Contract for One Million HIV Tests
SE Asia Latest Target Market in Growing Global Distributor Network HALIFAX, Aug. 5 /CNW/ - MedMir...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n\nSE Asia Latest Target Market in Growing Global Distributor Network\n\n\nHALIFAX, Aug. 5 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today\nthat it has expanded its global distribution network into Southeast Asia,\nwhere the Company's MiraWell(R) Rapid HIV Test (MiraWell HIV) will soon be\navailable to healthcare providers and their patients.\n\n\nAmerican Health Diagnostics LLC (AHD), a MedMira distribution agent in\nthe United States, has signed an exclusive distribution agreement for MiraWell\nHIV in select markets of the Southeast Asia region. Under the terms of the\nagreement AHD will purchase one million MiraWell HIV tests in the first year.\nTechnical training is slated to begin in August 2008 with product sales\nramping up throughout the year. AHD is working with its on-the-ground\nsub-distributors, to market, sell and promote MiraWell HIV in the territory.\n\n\n"Southeast Asia holds exciting market opportunities for MedMira and we\nare very pleased to extend our reach into this target region through the AHD\nchannel," said Hermes Chan, President and CEO of MedMira. "Over the past five\nyears, we have worked closely with AHD to support Cardinal Health in\nsuccessfully marketing and selling our Reveal(R) G3 HIV test in the United\nStates. Based on this model, we look forward to working with AHD and their\nsub-distribution partners to build a strong market base for MiraWell HIV and\nadditional MedMira products in the future."\n\n\nMiraWell HIV is built on the Company's patented rapid flow-through\ntechnology platform, which is the product engine behind MedMira's successful\nline of rapid HIV tests that have been approved in Canada, the United States,\nthe European Union, China, Russia, and India. MiraWell HIV is approved by\nChina's State Food and Drug Administration (SFDA). The test requires no\nspecialized training or equipment to perform, and uses a whole blood, serum or\nplasma specimen to deliver results in just three minutes. MiraWell HIV has an\nextended shelf-life with no refrigeration required, making it ideally suited\nfor all types of testing environments. All of MedMira's tests are manufactured\nin Canada under ISO and GMP standards.\n\n\n"Our relationship with MedMira and experience with...